ArticleBMC pediatrics2025
Sequential treatment strategy for biliary atresia: Kasai hepatoportoenterostomy-liver transplantation: a single-center retrospective comparative cohort study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo analyze and compare the efficacy of two treatment strategies for biliary atresia (BA) sequential treatment of Kasai hepatoportoenterostomy-liver transplantation and primary liver transplantation.
methodsA retrospective analysis was conducted on the clinical data of 300 patients with BA who underwent LT in our center. Among these patients, 225 underwent Kasai hepatoportoenterostomy - liver transplantation sequential treatment (Kasai-LT group), while 75 received primary liver transplantation (pLT group). Data on demographic characteristics, perioperative conditions, postoperative recovery, and complications were collected to analyze the efficacy, complication rates, and survival outcomes of the two treatment approaches.
resultsAfter propensity score matching analysis, there were no differences in postoperative liver function recovery between two groups. However, the Kasai-LT group had lower APRI, lower γ-GT level, and lower PELD scores when liver transplantation. The Kasai-LT group had shorter operative time, shorter PICU stay, shorter hospital stay with lower hospitalization cost. The incidence of hepatic artery complications and thoracoabdominal infections after LT was significantly higher in the pLT group compared to the Kasai-LT group. The 5-year recipient cumulative survival rate was 94.40% in the Kasai-LT group compared to 88.10% in the pLT group. Furthermore, the 5-year cumulative graft survival rate was 89.30% in the Kasai-LT group and 86.80% in the pLT group.
conclusionThe treatment of BA should follow Kasai-LT sequential treatment combined with individualized treatment plans to achieve better pre-transplantation general condition and reduce the incidence of postoperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.